Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Baden – page 58

865 clinical trials in Baden, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Baden at a glance
865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

865 trials in Baden

Open in trial search

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Study on the Effectiveness of Carboplatin and Olaparib for Patients with Triple-Negative Breast Cancer with Positive HRD Status

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group

Follicular lymphoma

Not recruiting

Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Takeda Development Center Americas Inc.

Study on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Study on the Effect of Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Medical University Of Vienna

Myelofibrosis

Not recruiting

Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Celgene Corp.

Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Gastric cancer+1

Not recruiting

Study on the Safety and Activity of S095029 and Pembrolizumab for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Drug Combination for Patients with Advanced AL Amyloidosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Neoplasm

Not recruiting

Study of Avapritinib for Children with Solid Tumors Linked to KIT or PDGFRA Signaling

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Avapritinib
  • Sponsor:Blueprint Medicines Corp.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Baden

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer evaluating personalized treatment approaches using targeted therapies.

  • Adjuvant therapy optimization
  • Personalized treatment strategies
  • Novel drug combinations

Studies aim to improve survival rates through dynamic marker-adjusted therapeutic approaches.

02 Triple-Negative Breast Cancer

Research examining neoadjuvant treatment options for patients with early-stage triple-negative breast cancer, comparing innovative therapeutic combinations.

  • Treatment response assessment
  • Immunotherapy combinations
  • Survival outcome evaluation

Focus on improving treatment efficacy in low-risk recurrence patients.

03 Ovarian Cancer Studies

Advanced research on HRD-positive high-grade ovarian cancer, investigating optimized treatment durations and maintenance therapy approaches.

  • Chemotherapy optimization
  • Maintenance therapy evaluation
  • Recurrence prevention strategies

Emphasis on improving outcomes for patients with no residual tumor after debulking surgery.

04 Leukemia Research

Groundbreaking studies in chronic lymphocytic leukemia (CLL) examining novel drug combinations for high-risk patients.

  • Targeted therapy combinations
  • High-risk patient treatment
  • Disease progression prevention

Investigation of innovative triple-combination therapies for improved patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.